Point72 Asset Management L.P. boosted its holdings in Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) by 114.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,000,000 shares of the biopharmaceutical company’s stock after acquiring an additional 1,600,000 shares during the quarter. Point72 Asset Management L.P. owned 2.69% of Sunesis Pharmaceuticals worth $2,160,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Wells Fargo & Company MN raised its position in Sunesis Pharmaceuticals by 42.7% in the 2nd quarter. Wells Fargo & Company MN now owns 1,341,151 shares of the biopharmaceutical company’s stock worth $975,000 after purchasing an additional 401,193 shares during the last quarter. A.R.T. Advisors LLC increased its stake in shares of Sunesis Pharmaceuticals by 33.9% in the 2nd quarter. A.R.T. Advisors LLC now owns 98,842 shares of the biopharmaceutical company’s stock valued at $72,000 after buying an additional 25,042 shares during the period. Algert Global LLC increased its stake in shares of Sunesis Pharmaceuticals by 226.1% in the 2nd quarter. Algert Global LLC now owns 67,014 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 46,464 shares during the period. Vanguard Group Inc. raised its position in shares of Sunesis Pharmaceuticals by 228.0% during the second quarter. Vanguard Group Inc. now owns 2,283,383 shares of the biopharmaceutical company’s stock worth $1,660,000 after acquiring an additional 1,587,157 shares during the last quarter. Finally, Northern Trust Corp raised its position in shares of Sunesis Pharmaceuticals by 54.8% during the second quarter. Northern Trust Corp now owns 165,769 shares of the biopharmaceutical company’s stock worth $120,000 after acquiring an additional 58,653 shares during the last quarter. 53.06% of the stock is currently owned by institutional investors and hedge funds.

SNSS has been the subject of a number of research reports. HC Wainwright reiterated a “hold” rating on shares of Sunesis Pharmaceuticals in a research report on Wednesday, November 13th. Zacks Investment Research raised Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a report on Saturday, November 16th. Finally, ValuEngine upgraded shares of Sunesis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $2.67.

Shares of SNSS stock opened at $0.41 on Wednesday. The firm’s 50 day moving average price is $0.51 and its two-hundred day moving average price is $0.73. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.56 and a current ratio of 4.56. Sunesis Pharmaceuticals, Inc. has a 52-week low of $0.20 and a 52-week high of $1.77. The stock has a market cap of $46.09 million, a PE ratio of -0.55 and a beta of 2.67.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.04. As a group, sell-side analysts predict that Sunesis Pharmaceuticals, Inc. will post -0.28 earnings per share for the current fiscal year.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.

Recommended Story: Why is the price-sales ratio important?

Institutional Ownership by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.